These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27110126)

  • 1. Prognostic values of aldehyde dehydrogenase 1 isoenzymes in ovarian cancer.
    Ma YM; Zhao S
    Onco Targets Ther; 2016; 9():1981-8. PubMed ID: 27110126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer.
    You Q; Guo H; Xu D
    Drug Des Devel Ther; 2015; 9():5087-97. PubMed ID: 26366059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic roles of ALDH1 isoenzymes in gastric cancer.
    Li K; Guo X; Wang Z; Li X; Bu Y; Bai X; Zheng L; Huang Y
    Onco Targets Ther; 2016; 9():3405-14. PubMed ID: 27354812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct prognostic values of ALDH1 isoenzymes in breast cancer.
    Wu S; Xue W; Huang X; Yu X; Luo M; Huang Y; Liu Y; Bi Z; Qiu X; Bai S
    Tumour Biol; 2015 Apr; 36(4):2421-6. PubMed ID: 25582316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mining distinct aldehyde dehydrogenase 1 (ALDH1) isoenzymes in gastric cancer.
    Shen JX; Liu J; Li GW; Huang YT; Wu HT
    Oncotarget; 2016 May; 7(18):25340-9. PubMed ID: 27015121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldehyde dehydrogenase 1 (ALDH1) isoform expression and potential clinical implications in hepatocellular carcinoma.
    Yang CK; Wang XK; Liao XW; Han CY; Yu TD; Qin W; Zhu GZ; Su H; Yu L; Liu XG; Lu SC; Chen ZW; Liu Z; Huang KT; Liu ZT; Liang Y; Huang JL; Xiao KY; Peng MH; Winkle CA; O'Brien SJ; Peng T
    PLoS One; 2017; 12(8):e0182208. PubMed ID: 28792511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
    Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.
    Ruscito I; Darb-Esfahani S; Kulbe H; Bellati F; Zizzari IG; Rahimi Koshkaki H; Napoletano C; Caserta D; Rughetti A; Kessler M; Sehouli J; Nuti M; Braicu EI
    Gynecol Oncol; 2018 Jul; 150(1):151-157. PubMed ID: 29753392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct prognostic values of four-Notch-receptor mRNA expression in ovarian cancer.
    Zhou X; Teng L; Wang M
    Tumour Biol; 2016 May; 37(5):6979-85. PubMed ID: 26662955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma.
    Flahaut M; Jauquier N; Chevalier N; Nardou K; Balmas Bourloud K; Joseph JM; Barras D; Widmann C; Gross N; Renella R; Mühlethaler-Mottet A
    BMC Cancer; 2016 Oct; 16(1):781. PubMed ID: 27724856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
    Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
    Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics and prognostic value of the cancer stem cell marker ALDH1 in ovarian cancer: a meta-analysis.
    Zhao W; Zang C; Zhang T; Li J; Liu R; Feng F; Lv Q; Zheng L; Tian J; Sun C
    Onco Targets Ther; 2018; 11():1821-1831. PubMed ID: 29662319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.
    Fischer AK; Pham DL; Bösmüller H; Lengerke C; Wagner P; Bachmann C; Beschorner C; Perner S; Kommoss S; Fend F; Staebler A
    Virchows Arch; 2019 Oct; 475(4):479-488. PubMed ID: 31451895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies.
    Tao Y; Li H; Huang R; Mo D; Zeng T; Fang M; Li M
    Cell Physiol Biochem; 2018; 46(4):1716-1726. PubMed ID: 29730663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome.
    Wang YC; Yo YT; Lee HY; Liao YP; Chao TK; Su PH; Lai HC
    Am J Pathol; 2012 Mar; 180(3):1159-1169. PubMed ID: 22222226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALDH1 Expression and Vasculogenic Mimicry Are Positively Associated with Poor Prognosis in Patients with Breast Cancer.
    Xing P; Dong H; Liu Q; Zhao T; Yao F; Xu Y; Chen B; Zheng X; Wu Y; Jin F; Li J
    Cell Physiol Biochem; 2018; 49(3):961-970. PubMed ID: 30184527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Musashi-1 Expression is a Prognostic Factor in Ovarian Adenocarcinoma and Correlates with ALDH-1 Expression.
    Chen PX; Li QY; Yang Z
    Pathol Oncol Res; 2015 Sep; 21(4):1133-40. PubMed ID: 25971681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co‑expression of
    Matsuoka I; Kasai T; Onaga C; Ozaki A; Motomura H; Maemura Y; Tada Y; Mori H; Hara Y; Xiong Y; Sato K; Tamori S; Sasaki K; Ohno S; Akimoto K
    Oncol Lett; 2024 Sep; 28(3):426. PubMed ID: 39021737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
    Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
    Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.